Federated Hermes’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Federated Hermes’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-6,485	Closed	-$28K	–	2240
2016 Q2	$28K	Hold	6,485	–	–	﹤0.01%	1725
2016 Q1	$36K	Hold	6,485	–	–	﹤0.01%	1696
2015 Q4	$112K	Buy	+6,485	New	+$155K	﹤0.01%	1559

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Federated Hermes's OREX Position: Q3 2016 in Review

Federated Hermes sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 6,485 shares — an estimated $28K sold.

Federated Hermes first reported a position in OREX in Q4 2015 and held it in 3 quarters. The position peaked at $112K in Q4 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

Federated Hermes reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Federated Hermes sold 6,485 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $28K.
Federated Hermes first reported a position in Orexigen Therapeutics, Inc. in Q4 2015 and held it in 3 quarters.
Federated Hermes's Orexigen Therapeutics, Inc. position peaked at $112K in Q4 2015.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Federated Hermes's 13F filing for Q3 2016, filed 10 Nov 2016.